Direct Occlusive Pumping
Roller pumps remain widely used because flow is familiar to perfusionists and can be configured for arterial, venous, suction and cardioplegia circuits.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (Single Roller Pump, Double Roller Pump), By Application (Cardiac Surgery, Lung Transplant Operation, Acute Respiratory Failure Treatment, Other Applications), By End User (Hospital Cardiac Centers, Specialty Heart Institutes, Academic & Teaching Hospitals, Other Advanced Care Facilities), By Technology Level (Conventional Systems, Integrated Monitoring Systems, Compact / Portable Systems), By Patient Group (Adult Perfusion, Pediatric & Neonatal Perfusion), and Regional Forecast, 2026-2034
The global heart lung machine market was valued at USD 328.1 million in 2025 and is estimated at USD 338.6 million in 2026. The market is projected to reach USD 435.0 million by 2034, representing a 3.2% CAGR during 2026–2034.
Heart lung machines, also known as cardiopulmonary bypass systems, temporarily replace the pumping function of the heart and gas-exchange function of the lungs during procedures requiring extracorporeal circulation. The system coordinates blood pumps, oxygenation, temperature management, monitoring, alarms and data-management functions so cardiac surgeons can operate on a still or decompressed heart.
The underlying clinical need remains durable because cardiovascular disease is the leading global cause of death. WHO reported 19.8 million cardiovascular deaths in 2022, while open-heart surgery, congenital repair, complex valve surgery and transplant procedures continue to require reliable perfusion support even as minimally invasive and off-pump techniques expand.
Technology is shifting from standalone modular pumps toward integrated perfusion platforms. LivaNova’s Essenz Perfusion System combines a heart-lung machine, patient monitor and in-line blood monitoring with operating-room connectivity, while Terumo’s Advanced Perfusion System 1 integrates central monitoring, safety modules and configurable pumps. This increases the value of software, sensing and workflow integration alongside the core pump hardware.
Source: WHO cardiovascular diseases; FDA Essenz HLM; LivaNova Essenz; Terumo Advanced Perfusion System 1.
The study defines the global heart lung machine market market by the equipment, application, end-user and technology boundaries listed below. The scope is structured to keep market sizing consistent with the commercial systems and services included in the syndicated study.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million |
| By Type | Single Roller Pump; Double Roller Pump |
| By Application | Cardiac Surgery; Lung Transplant Operation; Acute Respiratory Failure Treatment; Other Applications |
| By End User | Hospital Cardiac Centers; Specialty Heart Institutes; Academic & Teaching Hospitals; Other Advanced Care Facilities |
| By Technology Level | Conventional Systems; Integrated Monitoring Systems; Compact / Portable Systems |
| By Patient Group | Adult Perfusion; Pediatric & Neonatal Perfusion |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; Germany; France; United Kingdom; Italy; China; Japan; South Korea; India; Australia; Brazil; Mexico and other major markets |
| Key Market Players | LivaNova; Getinge / Maquet Cardiopulmonary; Terumo Cardiovascular Systems; Medtronic; Braile Biomedica; Tianjin Medical; Century HLM; Spectrum Medical |
The market includes capital heart-lung machine consoles and integrated perfusion platforms used to control and support cardiopulmonary bypass. Revenue includes roller-pump and integrated system hardware together with directly associated console-level monitoring and control modules when sold as part of the heart-lung machine platform.
Disposable oxygenators, tubing sets, cannulae, standalone extracorporeal membrane oxygenation systems and unrelated critical-care pumps are outside the core revenue boundary unless included as integrated heart-lung machine components or discussed as demand-influencing technologies.
WHO reported 19.8 million cardiovascular deaths in 2022. Heart-lung machines serve only the subset requiring open-heart or complex cardiothoracic surgery, but coronary, valve, congenital and transplant procedures create a persistent global requirement for perfusion infrastructure.
Heart-lung machines have long service lives and are typically purchased by high-acuity cardiac centers. Growth therefore depends heavily on replacement, upgrade and new-center installation rather than rapid annual turnover, which produces a steadier growth profile than many disposable cardiac devices.
Modern platforms combine pump control with blood-gas monitoring, temperature, pressure, level, bubble and data-management functions. This shifts hospital purchasing toward connected perfusion ecosystems that can reduce manual transcription and centralize safety information.
Selected coronary and valve procedures can be performed without full cardiopulmonary bypass. As less-invasive techniques expand, manufacturers must rely more on complex procedures, replacement cycles and higher-value integrated systems for growth.
Heart-lung machines are life-sustaining devices used during high-risk surgery. Redundant controls, battery backup, bubble sensing, alarms and manual fallback functions are key purchasing criteria and are closely scrutinized in post-market surveillance.
Source: WHO CVD; LivaNova Essenz; Terumo System 1; FDA heart-lung machine TPLC.
Essenz combines an HLM, patient monitor and in-line sensing and can connect with hospital information systems and external operating-room devices. Data integration can reduce fragmented monitoring and improve documentation across the procedure.
Current platforms integrate bubble detection, level sensing, alarms, pump-response features and central monitoring. Automation is not replacing the perfusionist but is reducing avoidable manual steps and helping standardize safety responses.
Terumo’s Advanced Perfusion System 1 is designed so components can be configured to match local practice. Modular architecture allows hospitals to tailor pump positions, monitoring modules and control functions without replacing the entire platform.
LivaNova states that more than 5.5 million patients have been treated with the S5 heart-lung machine. The persistence of mature installed systems means new products must offer compelling workflow, safety and service advantages to drive replacement.
FDA safety actions in 2026 involving Maquet cardiopulmonary components show that cable durability, sterile-barrier integrity and sensor reliability remain important even in mature perfusion technologies. Hospitals increasingly evaluate vendor service and risk-management capability alongside purchase price.
Source: LivaNova Essenz; LivaNova S5; Terumo System 1; FDA Maquet recall.
Heart-lung machine differentiation increasingly depends on safety architecture, sensing, control integration and data management as much as on the core pump mechanism.
Roller pumps remain widely used because flow is familiar to perfusionists and can be configured for arterial, venous, suction and cardioplegia circuits.
Modern systems combine multiple physiological and circuit sensors to support rapid recognition of adverse conditions and reduce dependence on separate standalone monitors.
Integrated user interfaces consolidate pump status, alarms and patient data, reducing visual clutter and manual cross-checking during complex procedures.
Connected platforms export perfusion data and can interface with operating-room and hospital information systems, supporting documentation and quality-improvement workflows.
Source: LivaNova Essenz; Terumo System 1.
By type, the market is segmented into single roller pump and double roller pump heart-lung machines. Single roller pump systems hold the leading position because they are widely used in standard cardiac-surgery workflows and offer familiar, cost-efficient operation.
Single roller pump systems lead the market because they suit a broad range of routine cardiopulmonary bypass procedures and provide established control characteristics for perfusion teams.
Double roller pump systems provide independent control of additional circuits and can support complex procedures requiring more simultaneous pumping functions. Their installed base is smaller but technically important.
Single roller pump systems are expected to retain the largest installed-base share, while double roller configurations remain important for complex perfusion setups and specialized cardiac centers.
By application, the market is segmented into cardiac surgery, lung transplant operation, acute respiratory failure treatment and other uses. Cardiac surgery remains the dominant application because cardiopulmonary bypass is central to many open-heart procedures.
Coronary bypass, valve surgery, congenital repair and complex aortic procedures create the primary commercial demand for heart-lung machines.
Transplant procedures can require extracorporeal circulatory and gas-exchange support, creating a specialized use case concentrated in advanced transplant centers.
Heart-lung machine technology overlaps with extracorporeal support concepts in severe respiratory failure, although dedicated ECMO platforms are usually the preferred long-duration technology.
Other uses include selected complex thoracic, vascular and research applications requiring temporary extracorporeal circulation.
Cardiac surgery will remain the principal application through 2034, while transplant and critical-care-adjacent uses support specialized demand in tertiary centers.
By end user, demand is concentrated in hospital cardiac centers, specialty heart institutes, academic and teaching hospitals, and other advanced-care facilities. Large hospital cardiac centers are the leading end user because full bypass requires intensive infrastructure and multidisciplinary teams.
Major cardiac hospitals lead purchasing because they perform high volumes of open-heart surgery and maintain dedicated perfusion departments, operating rooms and intensive care.
Dedicated cardiovascular institutes concentrate complex valve, congenital and bypass procedures and often adopt premium integrated perfusion platforms.
Teaching hospitals combine surgery with perfusion education, clinical research and complex referrals, supporting demand for flexible, data-rich systems.
Selected transplant, military and specialty surgical facilities use heart-lung machines where cardiopulmonary bypass capability is maintained.
Hospital cardiac centers will remain the dominant end user, while specialty institutes and teaching hospitals are likely to adopt the most advanced integrated monitoring and data-management configurations.
By technology level, the market is segmented into conventional systems, integrated monitoring systems and compact or portable systems. Integrated monitoring systems represent the main premium upgrade pathway in mature cardiac-surgery markets.
Conventional modular heart-lung machines remain widely used because of proven reliability, familiar controls and long service life.
Next-generation systems combine pump control, patient monitoring, in-line blood monitoring and data connectivity, increasing system value and improving workflow integration.
Compact systems target smaller operating rooms, mobile support and settings where footprint or transport flexibility is important, although adoption remains more limited than conventional systems.
Conventional systems will remain a large installed base, while integrated monitoring platforms should capture the strongest replacement-cycle value as hospitals modernize perfusion infrastructure.
By patient group, heart-lung machine use is segmented into adult perfusion and pediatric or neonatal perfusion. Adult procedures dominate volume, while pediatric cases require smaller circuits, lower priming volumes and more specialized perfusion management.
Adult cardiac surgery provides the largest demand base across coronary, valve and aortic procedures. Standard pump modules and monitoring configurations are designed primarily around adult flows and circuit sizes.
Pediatric and neonatal bypass requires precise low-flow control, reduced priming volumes, close temperature management and specialized disposables. Clinical complexity supports demand for advanced monitoring and highly trained perfusion teams.
Adult perfusion will remain the largest patient-group segment, while pediatric and neonatal surgery continues to require premium precision and specialist configurations.
Regional demand follows cardiac-surgery volume, perfusionist availability, hospital capital investment and replacement of aging systems. North America is the largest market, with Europe close behind and Asia-Pacific providing the strongest long-term expansion opportunity.
North America leads through a large installed base of cardiac centers, mature perfusion practice and early adoption of integrated systems. The syndicated market framework places regional share in the mid-30% range.
Europe combines major manufacturers, high open-heart surgery capability and established perfusion training. Germany, Italy, France and the United Kingdom maintain broad cardiac-surgery infrastructure.
China, India, Japan and South Korea are expanding cardiac-care infrastructure and specialist surgery capacity. Growth is strongest where new cardiac centers add perfusion capability rather than relying only on replacement.
Brazil and Mexico anchor regional demand, with capital budgets and perfusionist availability determining adoption outside major urban cardiac centers.
Gulf countries support premium cardiac-care investment, while broader regional penetration depends on tertiary-hospital infrastructure and specialized staff.
Source: WHO CVD; FDA Essenz.
Heart-lung machine consoles are life-sustaining Class II devices in the United States. Product development and post-market management therefore emphasize electrical safety, pump accuracy, alarms, sensor performance, battery backup, software and fail-safe operation.
| Framework / Event | Requirement or Development | Commercial Relevance |
|---|---|---|
| U.S. Class II device pathway | FDA classifies cardiopulmonary bypass heart-lung machine consoles under 21 CFR 870.4220. | Provides an established 510(k) pathway for substantially equivalent systems. |
| Essenz clearance | FDA cleared the Essenz HLM and integrated in-line blood monitor under K232291 in August 2023. | Supports commercialization of an integrated next-generation perfusion platform. |
| Post-market sensor reliability | FDA posted a Class II recall for a Maquet bubble sensor in February 2026 because cable damage could cause sensor failure or disconnection errors. | Shows the continuing importance of accessory reliability and preventive maintenance. |
| Sterile accessory integrity | A September 2026 Getinge cardiopulmonary bypass accessory recall involved sterile-barrier integrity concerns. | Reinforces supply-chain and quality-management requirements around the broader perfusion ecosystem. |
Source: FDA Essenz; FDA TPLC; FDA Maquet bubble sensor recall; FDA Getinge accessory recall.
The market is highly concentrated around established perfusion manufacturers with long installed bases and deep clinical service networks. Competition is driven by reliability, pump architecture, monitoring integration, data connectivity, training, service response and hospital standardization.
LivaNova competes through S5 and Essenz platforms, a large historical installed base and expansion into connected patient monitoring and in-line sensing.
Getinge combines established heart-lung machine platforms with a broad cardiopulmonary accessory and perfusion portfolio used in major cardiac centers.
Terumo’s Advanced Perfusion System 1 emphasizes modular configuration, safety monitoring and pump flexibility for institutional perfusion practice.
Other manufacturers compete through regional distribution, specialized pump systems, monitoring and value-oriented configurations.
Source: LivaNova Essenz; Terumo System 1.
September 2026: FDA posted a Class II recall involving selected Getinge/Maquet cardiopulmonary bypass insertion components because packaging might not consistently maintain sterile barrier integrity, highlighting continued quality-control requirements around perfusion accessories.
February 2026: FDA posted a Class II recall for a Maquet venous bubble sensor after internal investigations identified cable-durability issues that could lead to sensor defects or disconnection errors.
Current product cycle: LivaNova continues commercial rollout of the Essenz Perfusion System, combining the Essenz HLM with patient monitoring and integrated in-line blood sensing as hospitals modernize perfusion infrastructure.
Source: FDA Getinge recall; FDA Maquet bubble sensor recall; LivaNova Essenz.
The global heart lung machine market market is projected to grow from USD 338.6 million in 2026 to USD 435.0 million by 2034, at a 3.2% CAGR during 2026–2034. Growth is expected to remain steady rather than rapid because heart-lung machines are durable capital equipment with long replacement cycles. Value expansion will be driven by integrated monitoring, data connectivity, safety upgrades and new cardiac-center installations in Asia-Pacific and other developing markets.
| Forecast Variable | Current Evidence / Starting Point | Expected Effect Through 2034 |
|---|---|---|
| Cardiac disease burden | WHO reports 19.8 million cardiovascular deaths globally. | Supports durable demand for advanced cardiac intervention and surgery. |
| Replacement cycle | Large mature installed bases require periodic modernization. | Creates recurring capital-equipment demand even in mature regions. |
| Integrated monitoring | New systems combine pump control, sensing and patient monitoring. | Raises average system value and supports premium upgrades. |
| Safety lifecycle | FDA recalls show continuing attention to sensor, cable and sterile-barrier reliability. | Supports service, maintenance and quality differentiation. |
| Asia-Pacific expansion | New cardiac centers are increasing perfusion capacity. | Provides the strongest geographic installed-base growth opportunity. |
The study is structured to support strategy, market-entry assessment, portfolio planning, competitive benchmarking and commercial opportunity analysis across the global heart lung machine market landscape.
24LifeScience develops heart lung machine market market estimates using a combination of bottom-up and top-down assessment. Bottom-up work reviews relevant manufacturers, product portfolios, geographic presence, installation or utilization patterns, commercial channels and pricing structure. Top-down work evaluates the addressable testing or diagnostic environment, installed capacity, procedure or production demand, replacement and upgrade cycles, and regional access conditions.
Primary research is used to validate market structure, purchasing criteria, technology adoption, competitive positioning and operating constraints where available. Secondary research prioritizes regulators, government and public-health agencies, recognized standards, peer-reviewed or professional evidence, and company filings or official product communications. The analysis combines WHO cardiovascular-burden evidence, FDA device records, current perfusion-platform specifications and clinically relevant safety actions. Device categories, technology developments and company identities reflect current regulatory and manufacturer information.
Forecasts incorporate the 2025 market base, 2026 estimated conditions, technology and regulatory developments, replacement or expansion demand, regional investment, pricing pressure, service requirements and competitive intensity. High-impact assumptions are cross-checked against authoritative evidence before publication.
The market was valued at USD 328.1 million in 2025 and is estimated at USD 338.6 million in 2026. It is projected to reach USD 435.0 million by 2034 at a 3.2% CAGR during 2026–2034.
It temporarily replaces the pumping and gas-exchange functions of the heart and lungs during procedures requiring cardiopulmonary bypass.
Single roller pump systems are the leading type because they are widely used and familiar across standard cardiac-surgery perfusion workflows.
Cardiac surgery is the leading application, covering coronary bypass, valve, congenital and other open-heart procedures requiring extracorporeal circulation.
North America is the largest regional market, supported by a mature cardiac-surgery installed base and early adoption of integrated perfusion technology.
Integrated systems that combine pump control, patient monitoring, in-line sensing and data connectivity are the principal premium upgrade trend.
Long equipment replacement cycles, capital cost, shortage of skilled perfusionists and growth of selected off-pump or minimally invasive procedures limit faster market expansion.
The report profiles LivaNova, Getinge/Maquet, Terumo Cardiovascular, Medtronic, Braile Biomedica, Tianjin Medical, Century HLM and Spectrum Medical.
The standardized forecast period is 2026–2034, with 2025 as the base year and 2026 as the estimated year.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.